PL1761529T3 - Pochodne pirolopirydyny i ich zastosowanie jako antagonistów CRTh2 - Google Patents

Pochodne pirolopirydyny i ich zastosowanie jako antagonistów CRTh2

Info

Publication number
PL1761529T3
PL1761529T3 PL05751627T PL05751627T PL1761529T3 PL 1761529 T3 PL1761529 T3 PL 1761529T3 PL 05751627 T PL05751627 T PL 05751627T PL 05751627 T PL05751627 T PL 05751627T PL 1761529 T3 PL1761529 T3 PL 1761529T3
Authority
PL
Poland
Prior art keywords
crth2 antagonists
pyrrolopyridine derivatives
pyrrolopyridine
derivatives
crth2
Prior art date
Application number
PL05751627T
Other languages
English (en)
Other versions
PL1761529T6 (pl
Inventor
Kamlesh Bala
Catherine Leblanc
David Andrew Sandham
Katharine L Turner
Simon James Watson
Lyndon Nigel Brown
Brian Cox
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413619A external-priority patent/GB0413619D0/en
Priority claimed from GB0507693A external-priority patent/GB0507693D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1761529T3 publication Critical patent/PL1761529T3/pl
Publication of PL1761529T6 publication Critical patent/PL1761529T6/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
PL05751627T 2004-06-17 2005-06-16 Pochodne pirolopirydyny i ich zastosowanie jako antagonistów CRTh2 PL1761529T6 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0413619A GB0413619D0 (en) 2004-06-17 2004-06-17 Organic compounds
GB0507693A GB0507693D0 (en) 2005-04-15 2005-04-15 Organic compounds
PCT/EP2005/006493 WO2005123731A2 (en) 2004-06-17 2005-06-16 Pyrrolopyridine derivatives and their use as crth2 antagonists
EP05751627A EP1761529B3 (en) 2004-06-17 2005-06-16 Pyrrolopyridine derivatives and their use as crth2 antagonists

Publications (2)

Publication Number Publication Date
PL1761529T3 true PL1761529T3 (pl) 2008-04-30
PL1761529T6 PL1761529T6 (pl) 2011-11-30

Family

ID=35510318

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05751627T PL1761529T6 (pl) 2004-06-17 2005-06-16 Pochodne pirolopirydyny i ich zastosowanie jako antagonistów CRTh2

Country Status (28)

Country Link
US (5) US7666878B2 (pl)
EP (1) EP1761529B3 (pl)
JP (1) JP4886680B2 (pl)
KR (1) KR101183330B1 (pl)
AR (1) AR049443A1 (pl)
AT (1) ATE378338T1 (pl)
AU (1) AU2005254681B2 (pl)
BR (1) BRPI0512060B8 (pl)
CA (1) CA2569125C (pl)
CY (1) CY1107851T1 (pl)
DE (1) DE602005003365T3 (pl)
DK (1) DK1761529T3 (pl)
EC (1) ECSP067077A (pl)
ES (1) ES2294717T7 (pl)
HR (1) HRP20080022T4 (pl)
IL (1) IL179604A (pl)
MA (1) MA28666B1 (pl)
MX (1) MXPA06014694A (pl)
MY (1) MY144903A (pl)
NO (1) NO338319B1 (pl)
NZ (1) NZ551439A (pl)
PE (1) PE20060301A1 (pl)
PL (1) PL1761529T6 (pl)
PT (1) PT1761529E (pl)
RS (1) RS50552B (pl)
RU (1) RU2379309C2 (pl)
TW (1) TWI352702B (pl)
WO (1) WO2005123731A2 (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
CA2641880C (en) 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy
GB0611695D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
ATE530523T1 (de) 2006-08-07 2011-11-15 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate
CA2685540C (en) * 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
WO2009102462A1 (en) * 2008-02-15 2009-08-20 Abbott Laboratories Thienopyrroles and pyrrolothiazoles as new therapeutic agents
ES2572615T3 (es) 2008-08-15 2016-06-01 Nivalis Therapeutics, Inc. Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos
DK2315590T3 (da) * 2008-08-15 2012-11-19 N30 Pharmaceuticals Inc Pyrrolinhibitorer af S-nitrosoglutathionreduktase
US8470857B2 (en) * 2008-08-15 2013-06-25 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
AR080703A1 (es) 2010-03-22 2012-05-02 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
US9469615B2 (en) * 2010-12-23 2016-10-18 Merck Sharp & Dohme Corp. Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2752410B1 (en) 2011-10-25 2016-08-31 Shionogi & Co., Ltd. Heterocycle derivative having pgd2 receptor antagonist activity
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
PE20161177A1 (es) 2014-03-17 2016-11-18 Actelion Pharmaceuticals Ltd Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
CA2992987A1 (en) 2015-07-23 2017-01-26 Merck Sharp & Dohme Corp. Genetic markers associated with response to crth2 receptor antagonists
KR20180053345A (ko) 2015-09-15 2018-05-21 이도르시아 파마슈티컬스 리미티드 결정질 형태
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
KR20180058724A (ko) * 2015-09-29 2018-06-01 노파르티스 아게 1-(4-메탄술포닐-2-트리플루오로메틸-벤질)-2-메틸-1H-피롤로 [2,3-b]피리딘-3-일-아세트산의 제조 방법
WO2017210261A1 (en) * 2016-05-31 2017-12-07 Concert Pharmaceuticals, Inc. Deuterated fevipiprant
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
CN106188040B (zh) * 2016-06-28 2018-03-23 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法
US11524958B2 (en) 2016-07-21 2022-12-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound as CRTH2 inhibitor
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
EP3601235B1 (en) 2017-03-30 2026-03-04 XWPharma Ltd. Bicyclic heteroaryl derivatives, preparation and therapeutic uses thereof
JOP20190223A1 (ar) * 2017-04-01 2019-09-26 Novartis Ag عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
CA3067746A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
WO2019011336A1 (zh) * 2017-07-14 2019-01-17 苏州科睿思制药有限公司 Qaw-039的晶型及其制备方法和用途
WO2019130166A1 (en) * 2017-12-26 2019-07-04 Mankind Pharma Ltd. Preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoro methyl)phenyl]methyl] pyrrolo[2,3-b]pyridin-3-yl]acetic acid
CA3088917A1 (en) 2018-01-19 2019-07-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form of indole derivative and preparation method and use thereof
CN110467612B (zh) * 2018-05-09 2020-09-25 新发药业有限公司 一种前列腺素d2受体抑制剂化合物的简便制备方法
CN114042070A (zh) 2018-09-30 2022-02-15 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
TWI899126B (zh) 2019-12-20 2025-10-01 香港商凱瑞康寧有限公司 ４－纈胺醯氧基丁酸的合成方法
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程（武汉）有限公司 水溶性活性药物成分的控制释放制粒
AU2021293941B2 (en) 2020-06-18 2024-03-28 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
WO2022006040A1 (en) 2020-06-30 2022-01-06 The Regents Of The University Of California Compositions and methods for modulating hair growth
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320268A (en) 1964-08-14 1967-05-16 Merck & Co Inc 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
GB9319297D0 (en) 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
JPH10510510A (ja) 1994-06-09 1998-10-13 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
DK0765327T3 (da) * 1994-06-16 1999-11-29 Pfizer Pyrazolo- og pyrrolopyridiner
TWI262920B (en) 2000-10-27 2006-10-01 Elbion Ag New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
EP1424325A4 (en) * 2001-09-07 2005-12-21 Ono Pharmaceutical Co INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231509A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
IL179604A0 (en) 2007-05-15
RS50552B (sr) 2010-05-07
ES2294717T7 (es) 2012-06-14
DK1761529T3 (da) 2008-03-25
US20100210610A1 (en) 2010-08-19
BRPI0512060A (pt) 2008-02-06
DE602005003365T2 (de) 2008-09-11
DE602005003365T3 (de) 2012-08-30
US8470848B2 (en) 2013-06-25
ES2294717T3 (es) 2008-04-01
US20140309254A1 (en) 2014-10-16
US9169251B2 (en) 2015-10-27
PL1761529T6 (pl) 2011-11-30
AU2005254681A1 (en) 2005-12-29
AU2005254681B2 (en) 2009-01-29
RU2007101277A (ru) 2008-07-27
US8791256B2 (en) 2014-07-29
EP1761529A2 (en) 2007-03-14
DE602005003365D1 (de) 2011-01-05
CA2569125C (en) 2013-01-08
CA2569125A1 (en) 2005-12-29
NO338319B1 (no) 2016-08-08
US8455645B2 (en) 2013-06-04
US20130267518A1 (en) 2013-10-10
US20080114022A1 (en) 2008-05-15
IL179604A (en) 2014-04-30
PE20060301A1 (es) 2006-05-18
US7666878B2 (en) 2010-02-23
HRP20080022T3 (en) 2008-02-29
HK1103730A1 (en) 2007-12-28
WO2005123731A3 (en) 2006-05-04
NO20070323L (no) 2007-03-12
EP1761529B3 (en) 2011-06-15
MXPA06014694A (es) 2007-02-12
TW200617009A (en) 2006-06-01
PT1761529E (pt) 2008-02-11
MY144903A (en) 2011-11-30
BRPI0512060B8 (pt) 2021-05-25
JP2008502638A (ja) 2008-01-31
NZ551439A (en) 2009-09-25
RU2379309C2 (ru) 2010-01-20
CY1107851T1 (el) 2013-06-19
BRPI0512060B1 (pt) 2018-08-07
KR20070032694A (ko) 2007-03-22
KR101183330B1 (ko) 2012-09-17
EP1761529B1 (en) 2007-11-14
HRP20080022T4 (hr) 2011-10-31
MA28666B1 (fr) 2007-06-01
ATE378338T1 (de) 2007-11-15
US20100204225A1 (en) 2010-08-12
AR049443A1 (es) 2006-08-02
WO2005123731A2 (en) 2005-12-29
TWI352702B (en) 2011-11-21
ECSP067077A (es) 2007-01-26
JP4886680B2 (ja) 2012-02-29

Similar Documents

Publication Publication Date Title
IL179604A0 (en) Pyrrolopyridine derivatives and their use as crth2 antagonists
IL216734A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL178414A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL196021A0 (en) Pyrazolopyridine derivatives uses
PL1919894T3 (pl) Nowe pochodne polichinolin i ich zastosowanie terapeutyczne
ZA200606678B (en) 2-Pyridinylethylcarboxamide derivatives and their use as fungicides
IL179603A0 (en) Pyrrolopyridine derivatives
IL184008A0 (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
IL178461A0 (en) Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
IL178765A0 (en) 2-pyridinylcycloalkylbenzamide derivatives and their use as fungicides
IL182385A0 (en) Pyridine derivatives and the preparation and the therapeutic use thereof
IL180303A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
ZA200810629B (en) Phenylpentadienoyl derivatives and their use as par 1 antagonists
SI1761529T1 (sl) Derivati pirolopiridina in njihova uporaba kot antagonisti CRTh2
EP1810976A4 (en) BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND THE USE THEREOF
ZA200704650B (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
ZA200609864B (en) Pyrrolopyridine derivatives
IL183705A0 (en) Macrocyclic quinazole derivatives and their use as mtki
GB0406014D0 (en) Pharmaceutical composition and use
GB0411891D0 (en) New aminopyridine derivatives and their use as pharmaceuticals
GB0412463D0 (en) New aminopyridine derivatives and their use as pharmaceuticals
ZA200705046B (en) Macrocyclic quinazole derivatives and their use as MTKI
GB0401244D0 (en) Compounds and their use
GB0409377D0 (en) Compounds and their use